Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 09:06 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19:
NCT04695704 · Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina · PHASE3 · terminated · last registry update 2024-07-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The incidence of respiratory Long COVID has decreased in the new waves, thus made impossible to achieve the required study sample.” | – | Registry record, Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CYSLTR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-05-30Results posted on the registry: University of Colorado, Denver, Montelukast (NCT05362474)
- 2025-05-30Also stopped (terminated): University of Colorado, Denver, Montelukast (NCT05362474)
- 2025-01-22Results posted on the registry: National Cancer Institute (NCI), Ibrutinib + Steroid pulse (prednisone) (NCT04294641)
- 2024-12-24Phase 3 first posted: Phramongkutklao College of Medicine and Hospital, Montelukast + Montelukast Placebo (NCT06747130)
- 2024-11-26Also stopped (terminated): Chia Tai Tianqing Pharmaceutical Group Co., Ltd., TQC3564 tablets + Placebo tablets (NCT05607446)
- 2024-11-18Also stopped (withdrawn): Vanderbilt University Medical Center, Montelukast Oral Granules (NCT03277170)
- 2024-08-16Results posted on the registry: Susanna Naggie, MD, Montelukast (NCT05894577)
- 2024-05-28Phase 3 first posted: University of KwaZulu, Budesonide/formoterol + standard of care (NCT06429475)
- 2024-04-02Phase 3 first posted: South Valley University, Montelukast 10 Mg Oral Tablet (NCT06340984)
- 2024-03-07Results posted on the registry: Emory University, Montelukast + Placebo oral tablet (NCT03991988)
- 2023-11-02Phase 3 first posted: Mostafa Bahaa, levodopa-carbidopa + Montelukast (NCT06113640)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision